ADVISORY/FDA Approves Marketing Of Checkmate System for Coronary Artery Disease
Until now, no development has been able to overcome the obstacle of recurrent blockages, in treated coronary artery lesions. Cordis Corporation -- the Johnson & Johnson company that pioneered the cardiovascular stent -- announced U.S. Food and Drug Administration (FDA) approval to market the CHECKMATE(TM) System, the first intravascular brachytherapy (radiation) system for recurrent blockages in coronary arteries previously treated with coronary artery stents, the tiny mesh braces used to prop open narrowed heart vessels.
You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?1447
This multimedia news story is for free and unrestricted use on your news or information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics, and photos.
If you have any questions about the story, or about Newstream.com, please write to us at email@example.com.